Enhancing Exposure-Response Insights with a Pharmaverse Framework

The absence of a standardized approach for Exposure-Response (ER) modeling in clinical research has long hampered the efficiency of data analyses across studies. With drug development timelines accelerating, the need for a cohesive framework to streamline dataset creation is becoming increasingly critical. Recently, the Clinical Data Interchange Standards Consortium (CDISC) has taken a significant step in this direction by providing a clear structure for Population Pharmacokinetic (PopPK) analysis datasets through its 2023 Implementation Guide. However, ER modeling, which builds on PopPK outputs, remains without a comparable standard.

Unpacking the Current Standards Gap

Currently, inconsistencies abound among ER analyses: disparate variable names, varying exposure metrics, and differing dataset structures mean that every research team essentially starts from scratch when preparing their data. This lack of standardization not only complicates the pooling of data across studies but also hinders automation efforts, making programming in these studies more cumbersome. As turnaround times in drug development continue to shrink, these inefficiencies could prove detrimental to timely and effective patient outcomes.

Introducing a Structured Framework for ER Analysis

Recognizing the shared structural components between ER datasets and PopPK datasets—such as numeric covariates and pharmacokinetic exposure metrics—a new framework has been proposed. This initiative aims to extend CDISC's Analysis Data Model (ADaM) principles utilized in PopPK into the ER space, thus providing a structured pathway for ER dataset creation.

As part of this framework, discussions with the CDISC ADaM working group are encouraging. The group has shown interest in elevating this framework to a Knowledge Article or Examples Document, embedding the new ER datasets within existing CDISC standards and solidifying their foundational ties to the 2023 PopPK Implementation Guide. Although formal approval is still pending, the momentum surrounding this initiative is promising.

Key Datasets in the Proposed Framework

The proposed framework introduces four specialized datasets, each designed to target specific aspects of ER analysis:

These datasets build upon traditional ADaM datasets, facilitating the creation of analysis-ready datasets without the need for extensive data wrangling. Presented at PHUSE US Connect 2026, these developments are also documented in detail in a paper available for public access.

Leveraging the Pharmaverse Ecosystem

The implementation of this framework relies on the pharmaverse ecosystem, specifically tools such as {admiral}, {metacore}, and {xportr}. This toolchain was purposefully selected for its compatibility in creating ER datasets. For instance, {admiral} promotes incremental dataset development with modular derivation functions, while its assert functions catch errors early in the development cycle. The open-source nature of these tools ensures that advancements benefit the broader community.

A Move Toward Real-World Application

The R code for the proposed ER datasets is now publicly accessible, serving as a template for implementation. Users can adapt this code to their specific study needs, facilitating immediate reproduction of their datasets. The goal is not merely to create a framework but to establish it as a living standard through real-world application and community engagement.

Call for Community Collaboration

This is just the beginning. The framework remains a proposal, necessitating rigorous community validation through pilot testing and collaborative feedback. Clinical programmers are encouraged to engage with the code, testing its logic and identifying edge cases. Meanwhile, ER modelers and pharmacometricians must assess if the structure adequately meets their modeling needs. Their insights are vital for ensuring that the framework is functional and scientifically valid.

The development of a viable ER standard hinges on active participation from the community. As discussions progress, the aim is to foster an environment of collective advancement where insights and improvements circulate back to inform future iterations of the framework.

In summary, while the journey to a robust ER modeling standard is far from complete, the steps taken thus far are significant. The resistance to change in data management practices could yield great benefits, not only in enhancing efficiency but in ensuring that drug development leads to timely, data-driven decisions that ultimately improve patient outcomes. The increased collaboration across teams and organizations will be essential in paving the way for future standards within this evolving domain.